
    
      In Part A, study therapy will be administered as separate products, each taken q.d. by mouth.
      In Part B and Part C, participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg
      + RZR 30 mg q.d. by mouth.
    
  